Photocure - Asset Resilience Ratio
Photocure (PHO) has an Asset Resilience Ratio of 35.56% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check PHO strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how Photocure's Asset Resilience Ratio has changed over time. See how leveraged is Photocure's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Photocure's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Photocure market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr247.77 Million | 35.56% |
| Short-term Investments | Nkr0.00 | 0% |
| Total Liquid Assets | Nkr247.77 Million | 35.56% |
Asset Resilience Insights
- Very High Liquidity: Photocure maintains exceptional liquid asset reserves at 35.56% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Photocure Industry Peers by Asset Resilience Ratio
Compare Photocure's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
Haleon plc
NYSE:HLN |
Drug Manufacturers - Specialty & Generic | 4.06% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.62% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shenzhen Kangtai Biological Products Co Ltd
SHE:300601 |
Drug Manufacturers - Specialty & Generic | 12.24% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
Annual Asset Resilience Ratio for Photocure (2000–2024)
The table below shows the annual Asset Resilience Ratio data for Photocure.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 39.08% | Nkr288.83 Million ≈ $30.39 Million |
Nkr739.09 Million ≈ $77.77 Million |
+3.08pp |
| 2023-12-31 | 36.00% | Nkr256.34 Million ≈ $26.97 Million |
Nkr711.97 Million ≈ $74.92 Million |
-0.80pp |
| 2022-12-31 | 36.81% | Nkr264.65 Million ≈ $27.85 Million |
Nkr719.03 Million ≈ $75.66 Million |
-3.60pp |
| 2021-12-31 | 40.40% | Nkr319.04 Million ≈ $33.57 Million |
Nkr789.65 Million ≈ $83.09 Million |
-2.06pp |
| 2020-12-31 | 42.46% | Nkr329.53 Million ≈ $34.68 Million |
Nkr776.05 Million ≈ $81.66 Million |
-4.63pp |
| 2019-12-31 | 47.10% | Nkr121.20 Million ≈ $12.75 Million |
Nkr257.35 Million ≈ $27.08 Million |
-31.46pp |
| 2018-12-31 | 78.56% | Nkr181.62 Million ≈ $19.11 Million |
Nkr231.20 Million ≈ $24.33 Million |
-7.45pp |
| 2017-12-31 | 86.00% | Nkr226.28 Million ≈ $23.81 Million |
Nkr263.10 Million ≈ $27.69 Million |
+84.36pp |
| 2015-12-31 | 1.64% | Nkr4.08 Million ≈ $428.81K |
Nkr248.06 Million ≈ $26.10 Million |
+0.17pp |
| 2014-12-31 | 1.48% | Nkr4.00 Million ≈ $420.39K |
Nkr270.58 Million ≈ $28.47 Million |
+1.44pp |
| 2013-12-31 | 0.04% | Nkr117.00K ≈ $12.31K |
Nkr301.73 Million ≈ $31.75 Million |
-0.94pp |
| 2012-12-31 | 0.98% | Nkr4.24 Million ≈ $446.49K |
Nkr432.98 Million ≈ $45.56 Million |
+0.18pp |
| 2011-12-31 | 0.80% | Nkr4.09 Million ≈ $430.81K |
Nkr509.18 Million ≈ $53.58 Million |
-66.19pp |
| 2010-12-31 | 66.99% | Nkr344.24 Million ≈ $36.22 Million |
Nkr513.84 Million ≈ $54.07 Million |
-16.26pp |
| 2009-12-31 | 83.25% | Nkr380.33 Million ≈ $40.02 Million |
Nkr456.86 Million ≈ $48.08 Million |
+82.01pp |
| 2008-12-31 | 1.24% | Nkr2.94 Million ≈ $309.69K |
Nkr237.85 Million ≈ $25.03 Million |
+0.30pp |
| 2007-12-31 | 0.94% | Nkr2.82 Million ≈ $296.96K |
Nkr301.39 Million ≈ $31.72 Million |
-55.04pp |
| 2005-12-31 | 55.98% | Nkr59.17 Million ≈ $6.23 Million |
Nkr105.70 Million ≈ $11.12 Million |
-11.23pp |
| 2004-12-31 | 67.20% | Nkr116.74 Million ≈ $12.28 Million |
Nkr173.71 Million ≈ $18.28 Million |
-6.68pp |
| 2003-12-31 | 73.88% | Nkr172.44 Million ≈ $18.15 Million |
Nkr233.40 Million ≈ $24.56 Million |
+1.12pp |
| 2002-12-31 | 72.76% | Nkr217.55 Million ≈ $22.89 Million |
Nkr299.01 Million ≈ $31.46 Million |
-16.58pp |
| 2001-12-31 | 89.34% | Nkr285.49 Million ≈ $30.04 Million |
Nkr319.57 Million ≈ $33.63 Million |
-1.80pp |
| 2000-12-31 | 91.13% | Nkr368.95 Million ≈ $38.82 Million |
Nkr404.85 Million ≈ $42.60 Million |
-- |
About Photocure
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced ce… Read more